BP’s BioMarin Pharmaceuticals BMRN Stock Holding History

BP’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,509	Closed	-$376K	–	79
2021 Q2	$376K	Sell	4,509 -1,924	-30%	-$153K	0.02%	487
2021 Q1	$486K	Sell	6,433 -1,802	-22%	-$147K	0.02%	477
2020 Q4	$721K	Sell	8,235 -8,865	-52%	-$703K	0.02%	411
2020 Q3	$1.3M	Sell	17,100 -1,400	-8%	-$142K	0.03%	377
2020 Q2	$2.28M	Hold	18,500	–	–	0.08%	252
2020 Q1	$1.56M	Hold	18,500	–	–	0.07%	282
2019 Q4	$1.56M	Buy	+18,500	New	+$1.4M	0.05%	347
2019 Q1	–	Sell	-19,000	Closed	-$1.62M	–	390
2018 Q4	$1.62M	Sell	19,000 -3,000	-14%	-$285K	0.07%	285
2018 Q3	$2.13M	Hold	22,000	–	–	0.07%	300
2018 Q2	$2.07M	Buy	+22,000	New	+$1.93M	0.07%	305
2018 Q1	–	Sell	-20,000	Closed	-$1.78M	–	431
2017 Q4	$1.78M	Hold	20,000	–	–	0.06%	316
2017 Q3	$1.86M	Hold	20,000	–	–	0.07%	305
2017 Q2	$1.82M	Hold	20,000	–	–	0.07%	303
2017 Q1	$1.76M	Hold	20,000	–	–	0.07%	309
2016 Q4	$1.66M	Hold	20,000	–	–	0.06%	331
2016 Q3	$1.85M	Buy	+20,000	New	+$1.88M	0.07%	293
2015 Q4	–	Sell	-16,000	Closed	-$1.68M	–	289
2015 Q3	$1.68M	Sell	16,000 -5,000	-24%	-$668K	0.08%	249
2015 Q2	$2.87M	Hold	21,000	–	–	0.11%	222
2015 Q1	$2.62M	Buy	+21,000	New	+$2.23M	0.08%	245

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BP's BMRN Position: Q3 2021 in Review

BP sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 4,509 shares — an estimated $376K sold.

BP first reported a position in BMRN in Q1 2015 and held it in 19 quarters. The position peaked at $2.87M in Q2 2015. 513 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

BP reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
BP sold 4,509 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $376K.
BP first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 19 quarters.
BP's BioMarin Pharmaceuticals position peaked at $2.87M in Q2 2015.
513 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on BP's 13F filing for Q3 2021, filed 10 Nov 2021.